To evaluate canrenone effects compared to other therapies on cardiovascular mortality in patients with congestive heart failure and preserved systolic function after 12 years of evaluation.
The investigators will verify patients with cardiac heart failure (CHF) and preserved systolic function and each patient must have all clinical evaluation through basal measurements of blood pressure, heart rate, biochemical tests, and color Doppler echocardiographic parameters for at least 12 years. The investigators will evaluate the effects of an aldosterone antagonist as canrenone compared to a group without canrenone and the investogators will verify how many patients reported cardiovascular mortality or will survive.
Study Type
OBSERVATIONAL
Enrollment
502
Evaluation of canrenone therapy in patients with CHF
IRCCS Policlinico San Matteo
Pavia, Italy
Progression of CHF
Echocardiografic data
Time frame: 12 years
Haemodynamic data
Systolic blood pressure (SBP, Diastolic blood pressure (DBP), Heart rate (HR)
Time frame: 12 years
Metabolic data
fasting plasma glucose (FPG), total cholesterol (TC), HDL-cholesterol (HDL-C), triglycerides (Tg), LDL-cholesterol (LDL-C), lipoprotein (a) \[Lp(a)\],
Time frame: 12 years
Renal function
Sodium, Potassium, Creatinine, Uric acid
Time frame: 12 years
Endocrine data
Aldosterone, Plasma brain natriuretic peptide (BNP), Plasma renin activity (PRA)
Time frame: 12 years
Cardiovascular mortality
Register data
Time frame: 12 years
Survival
Register data
Time frame: 12 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.